The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling

Nature Communications

Volumn 6, Issue , 2015, Pages

  Chakraborty, Atanu ^a   Diefenbacher, Markus E ^a   Mylona, Anastasia ^a   Kassel, Olivier ^b   Behrens, Axel ^a,c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; RAF PROTEIN; RAS PROTEIN; RING DOMAIN AP1 COACTIVATOR 1; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE; SURFACTANT PROTEIN C; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ELK 1; TRIPARTITE MOTIF CONTAINING 7 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CARRIER PROTEIN; MITOGEN AND STRESS-ACTIVATED PROTEIN KINASE 1; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN C JUN; RNF187 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRIM7 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

CANCER; ENZYME ACTIVITY; GENE EXPRESSION; PROTEIN; RESPIRATORY DISEASE; TUMOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; EMBRYO; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG TUMOR; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RING FINGER MOTIF; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; PHOSPHORYLATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; HEK293 CELLS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MYC; RAF KINASES; RAS PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR AP-1; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84926612810     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7782     Document Type: Article

References (64)

1. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761-774 (2011).
2. Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290 (2007).
3. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003).
4. Shaulian, E. & Karin, M. AP-1 in cell proliferation and survival. Oncogene 20, 2390-2400 (2001).
5. Lamph, W. W., Wamsley, P., Sassone-Corsi, P. & Verma, I. M. Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature 334, 629-631 (1988).
6. Ryseck, R. P., Hirai, S. I., Yaniv, M. & Bravo, R. Transcriptional activation of c-jun during the G0/G1 transition in mouse fibroblasts. Nature 334, 535-537 (1988).
7. Wada, T. et al. MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat. Cell Biol. 6, 215-226 (2004).
8. Johnson, R. S., van Lingen, B., Papaioannou, V. E. & Spiegelmann, B. M. A null mutation at the c- jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev. 7, 1309-1317 (1993).
9. Schreiber, M. et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13, 607-619 (1999).
10. Johnson, R., Spiegelman, B., Hanahan, D. & Wisdom, R. Cellular transformation and malignancy induced by ras require c-jun. Mol. Cell Biol. 16, 4504-4511 (1996).
11. Mechta-Grigoriou, F., Gerald, D. & Yaniv, M. The mammalian Jun proteins: redundancy and specificity. Oncogene 20, 2378-2389 (2001).
12. Eferl, R. & Wagner, E. F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3, 859-868 (2003).
13. Davis, R. J. Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252 (2000).
14. Aguilera, C. et al. c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature 469, 231-235 (2011).
15. Davies, C. C. et al. Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activation. Nat. Cell Biol. 12, 963-972 (2010).
16. Davies, C. C., Chakraborty, A., Diefenbacher, M. E., Skehel, M. & Behrens, A. Arginine methylation of the c-Jun coactivator RACO-1 is required for c-Jun/ AP-1 activation. EMBO J. 32, 1556-1567 (2013).
17. Deshaies, R. J. & Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399-434 (2009).
18. Joazeiro, C. A. et al. The tyrosine kinase negative regulator c-Cbl as a RINGtype, E2-dependent ubiquitin-protein ligase. Science 286, 309-312 (1999).
19. Dalby, K. N., Morrice, N., Caudwell, F. B., Avruch, J. & Cohen, P. Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. J. Biol. Chem. 273, 1496-1505 (1998).
20. Deak, M., Clifton, A. D., Lucocq, L. M. & Alessi, D. R. Mitogen- and stressactivated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/ p38, and may mediate activation of CREB. EMBO J. 17, 4426-4441 (1998).
21. Kim, H. G. et al. Mitogen- and stress-activated kinase 1-mediated histone H3 phosphorylation is crucial for cell transformation. Cancer Res. 68, 2538-2547 (2008).
22. Chang, S., Iversen, L., Kragballe, K., Arthur, J. S. & Johansen, C. Mice lacking MSK1 and MSK2 show reduced skin tumor development in a two-stage chemical carcinogenesis model. Cancer Invest. 29, 240-245 (2011).
23. Perez-Cadahia, B. et al. Role of MSK1 in the malignant phenotype of Rastransformed mouse fibroblasts. J. Biol. Chem. 286, 42-49 (2011).
24. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
25. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
26. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064-1072 (2009).
27. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
28. Weir, B. A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007).
29. Kwei, K. A. et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27, 3635-3640 (2008).
30. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
31. Lee, W., Mitchell, P. & Tjian, R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49, 741-752 (1987).
32. Angel, P. et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49, 729-739 (1987).
33. Morton, S., Davis, R. J., McLaren, A. & Cohen, P. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J. 22, 3876-3886 (2003).
34. Ozato, K., Shin, D. M., Chang, T. H. & Morse, 3rd H. C. TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 8, 849-860 (2008).
35. Meroni, G. & Diez-Roux, G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. BioEssays 27, 1147-1157 (2005).
36. Hatakeyama, S. TRIM proteins and cancer. Nat. Rev. Cancer 11, 792-804 (2011).
37. Skurat, A. V., Dietrich, A. D., Zhai, L. & Roach, P. J. GNIP, a novel protein that binds and activates glycogenin, the self-glucosylating initiator of glycogen biosynthesis. J. Biol. Chem. 277, 19331-19338 (2002).
38. Gao, M. et al. Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 306, 271-275 (2004).
39. Gallagher, E., Gao, M., Liu, Y. C. & Karin, M. Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc. Natl Acad. Sci. USA 103, 1717-1722 (2006).
40. Hunter, T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol. Cell 28, 730-738 (2007).
41. Nguyen, L. K., Kolch, W. & Kholodenko, B. N. When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling. Cell Commun. Signal. 11, 52 (2013).
42. Laine, A. & Ronai, Z. Ubiquitin chains in the ladder of MAPK signaling. Sci. STKE 2005, re5 (2005).
43. Kubota, Y., O'Grady, P., Saito, H. & Takekawa, M. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat. Cell Biol. 13, 282-291 (2011).
44. Hsu, J. M. et al. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat. Cell Biol. 13, 174-181 (2011).
45. Andreu-Perez, P. et al. Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci. Signal. 4, ra58 (2011).
46. Gao, M. & Karin, M. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol. Cell 19, 581-593 (2005).
47. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
48. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
49. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
50. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
51. Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682 (2012).
52. Villanueva, J. et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep. 4, 1090-1099 (2013).
53. Morris, E. J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Dis. 3, 742-750 (2013).
54. Nissan, M. H., Rosen, N. & Solit, D. B. ERK pathway inhibitors: how low should we go? Cancer Dis. 3, 719-721 (2013).
55. Schneikert, J. et al. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J. Biol. Chem. 271, 23907-23913 (1996).
56. Diefenbacher, M. E. et al. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer. J. Clin. Invest. 124, 3407-3418 (2014).
57. Shimizu, N., Hashizume, T., Shingaki, K. & Kawamoto, J. K. Amplification of plasmids containing a mammalian replication initiation region is mediated by controllable conflict between replication and transcription. Cancer Res. 63, 5281-5290 (2003).
58. Campanero, M. R. & Flemington, E. K. Regulation of E2F through ubiquitin-proteasome- dependent degradation: stabilization by the pRB tumor suppressor protein. Proc. Natl Acad. Sci. USA 94, 2221-2226 (1997).
59. Vartiainen, M. K., Guettler, S., Larijani, B. & Treisman, R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. Science 316, 1749-1752 (2007).
60. Khokhlatchev, A. et al. Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases. J. Biol. Chem. 272, 11057-11062 (1997).
61. Nyabi, O. et al. Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. Nucleic Acids Res. 37, e55 (2009).
62. George, S. H. et al. Developmental and adult phenotyping directly from mutant embryonic stem cells. Proc. Natl Acad. Sci. USA 104, 4455-4460 (2007).
63. Sanceau, J., Poupon, M. F., Delattre, O., Sastre-Garau, X. & Wietzerbin, J. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 21, 7700-7709 (2002).
64. Perkins, D. N., Pappin, D. J., Creasy, D. M. & Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567 (1999).